Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
Sponsor: Unity Health Toronto
Summary
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.
Official title: Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
264
Start Date
2026-01-02
Completion Date
2027-04-24
Last Updated
2026-01-02
Healthy Volunteers
No
Interventions
Baloxavir
This is a sub-protocol within the TreatResp adaptive platform trial to compare the clinical and cost-effectiveness of Baloxavir, a single 40mg or 80 mg tablet based on patient weight, to a matching placebo among non-hospitalized patients with mild to moderate influenza A/B. This sub-protocol is part of the influenza domain within TreatResp.
Placebo Control
Matching placebo for Baloxavir
Locations (1)
Unity Health Toronto
Toronto, Ontario, Canada